Ipharma Ozempic/Tirzepatide Hybrid - Trizepsema Pen 34mg

Tirzepsema 34mg Hybrid Pen combines 30mg Tirzepatide + 4mg Semaglutide for advanced weight loss, appetite control, and metabolic support in one injection.

Tirzepsema 34mg Pre-Filled Pen IPH (RXME Hybrid) is a cutting-edge injectable designed to deliver maximum weight management and metabolic support in a convenient, once-weekly format.

This unique hybrid formula combines two of the most effective GLP-1 receptor agonists available today:

• 30mg Tirzepatide – a dual-action GLP-1 and GIP receptor agonist, enhancing appetite suppression, fat reduction, and improved insulin sensitivity.

• 4mg Semaglutide – a proven GLP-1 receptor agonist known for reducing cravings, increasing satiety, and supporting stable blood sugar levels.

By pairing these two compounds, Tirzepsema 34mg offers a synergistic effect, giving you stronger appetite control, better metabolic balance, and more sustainable results than using either alone.

Key Benefits:

• Dual-action GLP-1 + GIP activation for superior weight loss outcomes

• Combination of Semaglutide + Tirzepatide in one pen

• Reduces appetite and food cravings

• Improves blood sugar control and insulin response

• Convenient once-weekly pre-filled injection

• Premium IPH RXME formulation for trusted quality

Recommended For:
Adults seeking maximum results in their weight management journey with a clinically supported, next-generation hybrid peptide.